Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PBA-0111 |
| Synonyms | |
| Therapy Description |
PBA-0111 is an afucosylated monoclonal antibody that targets LRRC32 (GARP), which potentially prevents TGF-beta1-mediated immunosuppression and enhances antitumor immune response (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PBA-0111 | PBA 0111|PBA0111 | PBA-0111 is an afucosylated monoclonal antibody that targets LRRC32 (GARP), which potentially prevents TGF-beta1-mediated immunosuppression and enhances antitumor immune response (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06700070 | Phase I | PBA-0111 | A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors | Recruiting | USA | 0 |